Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy

Major Efficacy of Trabectedin in 2 Metastatic Osteosarcoma Patients with Wild-Type Asp1104 ERCC5 Tumor Status

(2013) Lauris Gastaud et al.   ONKOLOGIE

DNA Repair Inhibitors: The Next Major Step to Improve Cancer Therapy

(2012) Khaled Barakat et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Quality really matters: the need to improve specimen quality in biomedical research

(2012) Daniel Simeon-Dubach et al.   HISTOPATHOLOGY

Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

(2011) Jakob K. Anninga et al.   EUROPEAN JOURNAL OF CANCER

Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy

(2011) P Biason et al.   PHARMACOGENOMICS JOURNAL

Emerging drugs for high-grade osteosarcoma

(2010) Claudia Maria Hattinger et al.   EXPERT OPINION ON EMERGING DRUGS

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

(2009) D Caronia et al.   PHARMACOGENOMICS JOURNAL

Overcoming Glutathione S-Transferase P1-Related Cisplatin Resistance in Osteosarcoma

(2008) M. Pasello et al.   CANCER RESEARCH

Platinum Resistance: The Role of DNA Repair Pathways

(2008) L. P. Martin et al.   CLINICAL CANCER RESEARCH